RONALD J. BLOOMFIELD, M.D.; IAN J. WILSON, M.B., Ch.B.
To the editor: Nomifensine (Merital, Hoechst-Roussel, Somerville, New Jersey), a non-tricyclic antidepressant, was withdrawn from the worldwide market (1) in January 1986 after reports from Europe of serious and occasionally fatal hypersensitivity reactions, notably hemolytic anemia. The following case report appears to document the worst reaction to nomifensine in the United States. It supports previous reports suggesting an association between nomifensine and acute hemolytic anemia with subsequent acute renal failure.
A 32-year-old white female nurse took nomifensine for several months in 1985 for depression, with no complications. Later, against advice, she took one 50-mg capsule and within a few hours
BLOOMFIELD RJ, WILSON IJ. Nomifensine, Acute Hemolytic Anemia, and Renal Failure. Ann Intern Med. ;105:807. doi: 10.7326/0003-4819-105-5-807_1
Download citation file:
Published: Ann Intern Med. 1986;105(5):807.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use